glipizide has been researched along with ascorbic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Selvaag, E | 1 |
| Luo, M; O'Brien, RC | 1 |
1 review(s) available for glipizide and ascorbic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for glipizide and ascorbic acid
| Article | Year |
|---|---|
Photohemolytic potency of oral antidiabetic drugs in vitro: effects of antioxidants and a nitrogen atmosphere.
Topics: Antioxidants; Ascorbic Acid; Carbutamide; Chlorpropamide; Dose-Response Relationship, Drug; Gliclazide; Glipizide; Glyburide; Hemolysis; Humans; Hypoglycemic Agents; Nitrogen; Radiation-Sensitizing Agents; Reactive Oxygen Species; Sulfonamides; Sulfonylurea Compounds; Superoxide Dismutase; Tolazamide; Tolbutamide; Ultraviolet Rays; Vitamin E | 1996 |
The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro.
Topics: Administration, Oral; Adult; Antioxidants; Ascorbic Acid; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Sulfonylurea Compounds; Tolbutamide | 1997 |